{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:13:01Z","timestamp":1778584381550,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732118"],"award-info":[{"award-number":["2023M732118"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020QH265"],"award-info":[{"award-number":["ZR2020QH265"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QC179"],"award-info":[{"award-number":["ZR2023QC179"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QH074"],"award-info":[{"award-number":["ZR2021QH074"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QH276"],"award-info":[{"award-number":["ZR2021QH276"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022AB024"],"award-info":[{"award-number":["2022AB024"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203658"],"award-info":[{"award-number":["82203658"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100641"],"award-info":[{"award-number":["82100641"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370618"],"award-info":[{"award-number":["82370618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302067"],"award-info":[{"award-number":["82302067"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160124"],"award-info":[{"award-number":["82160124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.phrs.2025.107619","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T19:09:00Z","timestamp":1737400140000},"page":"107619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells"],"prefix":"10.1016","volume":"212","author":[{"given":"Minghao","family":"Sui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanli","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianni","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1843-4349","authenticated-orcid":false,"given":"Songbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.phrs.2025.107619_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2025.107619_bib2","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.ymthe.2021.01.021","article-title":"The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity","volume":"29","author":"Zou","year":"2021","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"10127","key":"10.1016\/j.phrs.2025.107619_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.phrs.2025.107619_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"25","key":"10.1016\/j.phrs.2025.107619_bib5","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2010.28.7805","article-title":"Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107619_bib6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00262-022-03349-4","article-title":"Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer Immunol., Immunother.: CII"},{"issue":"8","key":"10.1016\/j.phrs.2025.107619_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"issue":"20","key":"10.1016\/j.phrs.2025.107619_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cld.2022.08.004","article-title":"Hepatocellular carcinoma: new developments","volume":"27","author":"Ganesan","year":"2023","journal-title":"Clin. liver Dis."},{"key":"10.1016\/j.phrs.2025.107619_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.751159","article-title":"Lenvatinib plus immune checkpoint inhibitors improve survival in advanced hepatocellular carcinoma: a retrospective study","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.phrs.2025.107619_bib13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"28","key":"10.1016\/j.phrs.2025.107619_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn0881","article-title":"CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer","volume":"10","author":"Tarannum","year":"2024","journal-title":"Sci. Adv."},{"issue":"15","key":"10.1016\/j.phrs.2025.107619_bib16","first-page":"3979","article-title":"Chimeric Antigen Receptor-Glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase i trials, clinical cancer research: an official journal of the","volume":"26","author":"Shi","year":"2020","journal-title":"Am. Assoc. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107619_bib17","first-page":"690","article-title":"Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2025.107619_bib18","article-title":"New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma, Drug resistance updates: reviews and commentaries in antimicrobial and anticancer","volume":"51","author":"Bo","year":"2020","journal-title":"chemotherapy"},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib19","first-page":"47","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn, Nature reviews","volume":"21","author":"Albelda","year":"2024","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2025.107619_bib22","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"5","key":"10.1016\/j.phrs.2025.107619_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/2326-6066.CIR-18-0636","article-title":"Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies","volume":"7","author":"Ahn","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.phrs.2025.107619_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002173","article-title":"Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2025.107619_bib25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/protein\/gzq028","article-title":"Stability engineering of scFvs for the development of bispecific and multivalent antibodies, protein engineering, design & selection","volume":"23","author":"Miller","year":"2010","journal-title":"PEDS"},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2025.107619_bib27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107619_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.832765","article-title":"Special chimeric antigen receptor (CAR) modifications of T cells: a review","volume":"12","author":"Miao","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107619_bib29","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/2326-6066.CIR-19-0908","article-title":"Excessive costimulation leads to dysfunction of adoptively transferred T cells","volume":"8","author":"Wijewarnasuriya","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.107619_bib30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","article-title":"Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors","volume":"2","author":"Hirabayashi","year":"2021","journal-title":"Nat. Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2025.107619_bib31","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107619_bib32","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific GPC3\/PD\u20111 CAR\u2011T cells for the treatment of HCC","volume":"62","author":"Li","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107619_bib33","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","article-title":"GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy","volume":"39","author":"Lu","year":"2023","journal-title":"Cell Biol. Toxicol."},{"issue":"3","key":"10.1016\/j.phrs.2025.107619_bib34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ymthe.2023.01.002","article-title":"Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population","volume":"31","author":"Patra","year":"2023","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"10","key":"10.1016\/j.phrs.2025.107619_bib35","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1111\/febs.12126","article-title":"Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma","volume":"280","author":"Filmus","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.phrs.2025.107619_bib36","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2147\/IJN.S235058","article-title":"Preparation and characterization of anti-gpc3 nanobody against hepatocellular carcinoma","volume":"15","author":"Xia","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.phrs.2025.107619_bib37","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.phrs.2025.107619_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2025.107619_bib39","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.4049\/jimmunol.176.6.3585","article-title":"Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival","volume":"176","author":"Mincheva-Nilsson","year":"2006","journal-title":"J. Immunol. (Baltim., Md.: 1950)"},{"issue":"4","key":"10.1016\/j.phrs.2025.107619_bib40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1523-1747.2002.01700.x","article-title":"Expression of stress-induced MHC class I related chain molecules on human melanoma","volume":"118","author":"Vetter","year":"2002","journal-title":"J. Invest. Dermatol."},{"issue":"45","key":"10.1016\/j.phrs.2025.107619_bib41","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/onc.2008.272","article-title":"NKG2D ligands in tumor immunity","volume":"27","author":"Nausch","year":"2008","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.phrs.2025.107619_bib42","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of hepatocellular carcinoma by NKG2D-Based CAR-T Cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"12","key":"10.1016\/j.phrs.2025.107619_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003176","article-title":"Switch receptor T3\/28 improves long-term persistence and antitumor efficacy of CAR-T cells","volume":"9","author":"Zhao","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2025.107619_bib44","first-page":"951","article-title":"Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor","volume":"6","author":"Pan","year":"2021","journal-title":"Bioact. Mater."},{"issue":"2","key":"10.1016\/j.phrs.2025.107619_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003737","article-title":"Delivery of CD47 blocker SIRP\u03b1-Fc by CAR-T cells enhances antitumor efficacy","volume":"10","author":"Chen","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2025.107619_bib46","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99048","article-title":"Glioblastoma-targeted CD4+\u2009CAR T cells mediate superior antitumor activity","volume":"3","author":"Wang","year":"2018","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.phrs.2025.107619_bib47","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.phrs.2025.107619_bib48","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.phrs.2025.107619_bib49","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.immuni.2013.11.015","article-title":"New twist on an ancient innate immune pathway","volume":"39","author":"Lajoie","year":"2013","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.phrs.2025.107619_bib50","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.immuni.2013.10.018","article-title":"Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation","volume":"39","author":"Liszewski","year":"2013","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.phrs.2025.107619_bib51","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/0008-5472.CAN-17-3973","article-title":"In vitro priming of adoptively transferred T Cells with a ROR\u03b3 agonist confers durable memory and stemness in vivo","volume":"78","author":"Hu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2025.107619_bib52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaut.2015.08.006","article-title":"The protease cathepsin L regulates Th17 cell differentiation","volume":"65","author":"Hou","year":"2015","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.phrs.2025.107619_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nri3603","article-title":"Innate immunity: the inside story on complement activation","volume":"14","author":"Minton","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107619_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071611","article-title":"Identification of novel molecular markers of human Th17 Cells","volume":"9","author":"Sa\u0142kowska","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.phrs.2025.107619_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90772","article-title":"Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion","volume":"2","author":"Bowers","year":"2017","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.phrs.2025.107619_bib56","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ymthe.2023.04.010","article-title":"Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells","volume":"31","author":"Wyatt","year":"2023","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"3","key":"10.1016\/j.phrs.2025.107619_bib57","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.phrs.2025.107619_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","article-title":"THEMIS-SHP1 recruitment by 41bb tunes lck-mediated priming of chimeric antigen receptor-redirected T cells","volume":"37","author":"Sun","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.107619_bib59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.phrs.2025.107619_bib60","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjh.19348","article-title":"The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies","volume":"204","author":"Brillembourg","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.phrs.2025.107619_bib61","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:35:48Z","timestamp":1778582148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":61,"alternative-id":["S1043661825000441"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107619","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107619"}}